| pubmed-article:2045527 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2045527 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2045527 | lifeskim:mentions | umls-concept:C0341697 | lld:lifeskim |
| pubmed-article:2045527 | lifeskim:mentions | umls-concept:C0205307 | lld:lifeskim |
| pubmed-article:2045527 | lifeskim:mentions | umls-concept:C0022702 | lld:lifeskim |
| pubmed-article:2045527 | lifeskim:mentions | umls-concept:C0005508 | lld:lifeskim |
| pubmed-article:2045527 | lifeskim:mentions | umls-concept:C0055720 | lld:lifeskim |
| pubmed-article:2045527 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2045527 | pubmed:dateCreated | 1991-7-17 | lld:pubmed |
| pubmed-article:2045527 | pubmed:abstractText | To test the hypothesis that renal failure alters the disposition of cibenzoline in humans, an absolute bioavailability and elimination kinetic study was performed. We used the simultaneous administration of a stable isotope variant (SASIV). Eight healthy volunteers and eight matched hemodialysis patients each received simultaneously an 80-mg intravenous infusion of 15N-2-cibenzoline and a single 80-mg cibenzoline capsule. Cibenzoline plasma concentrations were assayed by a gas chromatographic-mass spectrometric assay. A compartment-independent kinetic analysis showed a plasma clearance of 707 mL/min and an elimination half-life of 7.3 hours after the intravenous dose in healthy volunteers. In renal-failure patients, cibenzoline clearance decreased to 224 mL/min and half-life increased to 22.4 hours. Decreased plasma clearance was due to decreases in both renal and nonrenal clearance. Absolute bioavailability was 83% and 90% in healthy volunteers and renal-failure patients, respectively. Hemodialysis accounted for only 13% of drug clearance. | lld:pubmed |
| pubmed-article:2045527 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2045527 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2045527 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2045527 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2045527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2045527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2045527 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2045527 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:2045527 | pubmed:issn | 0091-2700 | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:MayerM LML | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:SloanRR | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:BowerR JRJ | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:AronoffGG | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:AogaichiKK | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:MassarellaJJ | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:BarbalasMM | lld:pubmed |
| pubmed-article:2045527 | pubmed:author | pubmed-author:BrazzellRR | lld:pubmed |
| pubmed-article:2045527 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2045527 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:2045527 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2045527 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2045527 | pubmed:pagination | 38-44 | lld:pubmed |
| pubmed-article:2045527 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:meshHeading | pubmed-meshheading:2045527-... | lld:pubmed |
| pubmed-article:2045527 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2045527 | pubmed:articleTitle | Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function. | lld:pubmed |
| pubmed-article:2045527 | pubmed:affiliation | Department of Medicine, Indiana University School of Medicine, Indianapolis. | lld:pubmed |
| pubmed-article:2045527 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2045527 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2045527 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:2045527 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2045527 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2045527 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2045527 | lld:pubmed |
